Nasturtium officinale extract and its uses

A Nasturtium officinale hydrolyzate-based active ingredient addresses stress-related muscle tension and skin radiance issues by stimulating oxytocin and endocannabinoid pathways, offering immediate muscle relaxation and long-term skin smoothing benefits.

FR3149189A1Pending Publication Date: 2024-12-06SOCIETE INDUSTRIELLE LIMOUSINE D APPLICATION BIOLOGIQUE (SILAB)
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
FR2023005400
Authority / Receiving Office
FR · FR
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-31
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing cosmetic products derived from Nasturtium officinale do not effectively address the psychological and systemic effects of stress, including muscle tension and skin radiance issues, despite their known moisturizing and anti-wrinkle benefits.

Method used

An active ingredient comprising a hydrolyzate of Nasturtium officinale extract, rich in minerals and other compounds, is developed to stimulate the oxytocin and endocannabinoid pathways, promoting the expression of specific receptors and providing muscle relaxation and skin smoothing effects.

Benefits of technology

The extract significantly reduces stress levels by increasing oxytocin secretion and receptor expression, leading to immediate muscle relaxation and improved skin radiance, with noticeable effects within 6 hours and enhanced benefits after 28 days of use.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to an active ingredient obtained from a plant raw material of the species Nasturtium officinale and its uses, in particular to combat stress.
Need to check novelty before this filing date? Find Prior Art

Description

Title of the invention: Nasturtium officinale extract and its uses Technical field

[0001] The invention relates to an active ingredient obtained from a plant raw material of the species Nasturtium officinale and its uses, in particular for combating stress, in particular its harmful effects on health. State of the art

[0002] Psychological stress is defined as the set of psychological and physical reactions of the body allowing it to quickly overcome a dangerous, unexpected or worrying situation. If stress allowed our ancestors to escape the clutches of predators and thus undoubtedly contributed to the survival of the species, it is now chronically present in our daily lives with deleterious consequences on health. Stress is thus considered a real scourge and probably the illness of the century. Recently, the COVID-19 crisis has contributed to the increase in the level of general anxiety, a feeling due to the perception of a potential threat to the health and future of society.

[0003] At the cutaneous level, stress has, on the one hand, a significant behavioral impact resulting in a tightening of the facial muscles, causing the premature formation of characteristic expression lines. In order to virtually erase the harmful effects of stress on the skin, the use of photo retouching filters for social networks has become common practice. However, this practice is likely to accentuate the desire of consumers, often young people, to physically resemble retouched selfies and thus lead to a drop in self-esteem.

[0004] On the other hand, stress also has systemic cutaneous effects. Indeed, the skin is the site of secretions of stress neurotransmitters, the consequences of which are reflected in an alteration of the barrier function and a reduction in the radiance of the complexion.

[0005] There is therefore a need for an active ingredient to combat stress, but also its undesirable effects.

[0006] In this context, scientific studies have demonstrated the intimate biological link between psychological stress and the skin. Indeed, skin cells and neurons have many similarities and connections. The skin is richly innervated by a network of sensory fibers transmitting many perceived stimuli such as touch, temperature or even pain to the brain. It has thus been put highlighted the existence of specific and rapid paracrine communication from keratinocytes to sensory neurons via identical mediators and receptors, notably through the oxytocin and endocannabinoid pathways.

[0007] Oxytocin, also known as the "happy hormone," is described for its major role in reducing stress levels by providing a calming and well-being effect. This neurotransmitter is released by keratinocytes following activation of the PIEZO1 mechanoreceptor by gentle tactile stimulation, thus promoting their proliferation. Also, approaches designed to soothe the body and mind, based on relaxation, meditation or even sophrology, are already known in order to counter the systemic effects of stress.

[0008] Endocannabinoid receptors are also involved in the regulation of stress-induced mechanisms. At the cutaneous level, a period of acute psychological stress activates the signaling associated with the CB1 receptor, which allows an effective barrier function to be restored.

[0009] Also, the inventor was interested in a large number of plant raw materials capable of acting on stress and its consequences. These may be behavioral consequences of stress, for example the appearance of expression lines, but also systemic consequences of stress, for example irritability, sleep disorders, and alteration of the barrier function and parameters of complexion radiance.

[0010] During his research work, the inventor thus identified an extract of watercress and demonstrated its effectiveness on mediators of well-being, muscular contraction, but also its effectiveness on skin cells.

[0011] Thus, the inventor was particularly interested in the plant species Nasturtium officinale to develop a new ingredient derived from nature to act against stress. Products based on Nasturtium officinale are known, in particular cosmetic products having moisturizing and anti-wrinkle effects. However, none of these products describe an effectiveness linked to stress, in particular no effect on the receptors and mediators of "well-being" has been reported. This is the subject of the present invention. Summary of the invention

[0012] Thus, the invention relates to an extract of Nasturtium officinale, in particular an active ingredient comprising said extract of Nasturtium officinale for its cutaneous use to combat stress.

[0013] Indeed, the active ingredient according to the invention provides a “well-being” effect by promoting the expression of mediators and receptors of the stress response and has a myorelaxant action by acting on the neuromuscular junction. This double specific action neutralizes the harmful effects of stress on the skin and stimulates the production of the happiness hormone, reducing stress levels. As a result, the skin appears more relaxed, thus improving its quality. Thus, the active ingredient according to the invention is preferably intended to be used to combat the cutaneous effects of stress.

[0014] By acting on the cutaneous effects of stress, the active ingredient according to the invention makes it possible to combat the behavioral and systemic impact of stress. Preferably, the active ingredient according to the invention has a cutaneous myorelaxant effect, and consequently a smoothing effect. Particularly surprisingly, this smoothing effect is immediate. A significant improvement in neurostimulation is observed as early as 6 hours after application of the active ingredient according to the invention. Thus, the active ingredient according to the invention also stimulates the mediators and receptors of well-being.

[0015] Preferably, the invention also relates to the active ingredient according to the invention for its use for: - increase cutaneous oxytocin (OXT) secretion, and / or - increase the expression of the ion channel receptor PIEZO1, and / or - increase the expression of the oxytocin receptor OXTR, and / or - increase the synthesis of cannabinoid receptors, preferentially the cannabinoid receptor type 1 (CB1R).

[0016] According to another preferred embodiment, the invention also relates to the active ingredient according to the invention for its use in improving the radiance of the complexion.

[0017] The active ingredient according to the invention is an extract of Nasturtium officinale, also known as watercress.

[0018] Preferably, the extract of Nasturtium officinale is a hydrolyzate of Nasturtium officinale, more preferably, the hydrolyzate of Nasturtium officinale is an enzymatic hydrolyzate of Nasturtium officinale.

[0019] According to another preferred subject of the invention, the hydrolyzate of Nasturtium officinale comprises minerals. More preferably, the mineral ash represents at least 25% by weight of the total weight of the extract.

[0020] According to another preferred subject, the extract comprises at least one mineral, even more preferably a mixture of several minerals. Thus, the extract preferably comprises at least one mineral chosen from chlorides, sulfur, sodium, potassium, magnesium, phosphorus, calcium, and combinations thereof.

[0021] Finally, according to a last aspect, the invention also relates to a use, in particular cosmetic, of the active ingredient comprising at least one extract of Nasturtium officinale, according to any of the objects described above, for combating the cutaneous effects linked to stress and anxiety. Thus, the invention also relates to a cosmetic use of the active ingredient according to the invention for improve the radiance of the complexion and / or the smoothing effect.

[0022] Other characteristics and advantages will emerge from the detailed description of the invention, the examples and the figures which follow. Detailed description of the invention

[0023] Definition

[0024] For the purposes of the present invention, the term "extract of Nasturtium officinale" means at least one molecule or any molecule or mixture of at least two molecules obtained from a raw material, namely watercress, in particular the species Nasturtium officinale, regardless of the extraction process of said molecule(s). It may be, for example, an extract obtained by aqueous and / or hydroalcoholic and / or hydroglycolic extraction and / or obtained after at least one hydrolysis step, for example enzymatic or acid. Thus, for the purposes of the invention, such an extract is an ingredient derived from natural products obtained by specific and defined chemical and / or biological processes aimed at chemically modifying them, modifications which are intentional, and which make it possible to obtain structures of molecules which are therefore no longer all identical to the molecules present in nature.Most preferably, the extract of Nasturtium officinale is a hydrolyzate of Nasturtium officinale.

[0025] For the purposes of the invention, the term "Nasturtium officinale hydrolysate" means an extract from the plant species Nasturtium officinale, obtained by a process comprising at least one step of hydrolysis of Nasturtium officinale. The term Nasturtium officinale hydrolysate excludes processes of fermentation of Nasturtium officinale by a microorganism or an infusion / decoction / maceration of Nasturtium officinale.

[0026] By "active ingredient" within the meaning of the invention, we mean an extract comprising at least one molecule, preferably a set of molecules having an effect on stress, in particular to combat the cutaneous effects of stress.

[0027] By "fighting the cutaneous effects of stress" within the meaning of the invention, we mean an action aimed at stimulating the synthesis and expression of well-being mediators and receptors at the level of skin cells and / or exhibiting a myorelaxant action, for example by acting on the neuromuscular junction.

[0028] Active ingredient according to the invention

[0029] The present invention therefore relates to an active ingredient comprising at least one extract of Nasturtium officinale. Watercress, Nasturtium officinale, is a species of perennial plant of the Brassicaceae family, known since Antiquity for its nutritional and medicinal qualities as well as its richness in mineral elements. It is also known to be rich in flavonoids, vitamins and glucosinolates.

[0030] In this context, the inventor became interested in this plant raw material and developed an active ingredient based on an extract of Nasturtium officinale, which helps combat stress by acting in particular on the mediators and receptors of well-being. The active ingredient according to the invention advantageously promotes the expression of mediators and receptors of the stress response and has a muscle relaxant action by acting on the neuromuscular junction.

[0031] Access (as defined in the Nagoya Protocol) to the plant raw material (Nasturtium officinale) was carried out in accordance with the national APA (Access and Benefit Sharing) regulations of the country of origin (France).

[0032] The inventor characterized the molecules constituting the extract according to the invention and in particular determined the mineral content by weighing the residues resulting from incineration at 550°C in an electric muffle furnace to obtain the mineral ash content. The total sugar and protein contents were determined, respectively according to the DUBOIS method (Dubois M. et al., Analytical chemistry, 28, 3, 350-356, 1956) and the BCA method (Bincinchoninic acid; PK Smith et al. Measurement of protein using bicinchoninic acid, Anal. Biochem. 150, 1, 76, 1985).

[0033] Thus, the active ingredient according to the invention preferably comprises at least minerals and / or sugars, and / or proteins.

[0034] The inventor has characterized the nature of the mineral fraction of the extract according to the invention. Thus, according to an object of the invention, the extract of Nasturtium officinale comprises mineral ash, these advantageously representing at least 25% by weight of the total weight of the extract. Preferably, the extract comprises at least one mineral chosen from chlorides, sodium, potassium, sulfur, calcium, magnesium, phosphorus, and combinations thereof.

[0035] According to an object of the invention, the proteins present in the extract composing the active principle according to the invention preferably have a molar mass of less than 2,000 Da.

[0036] When the extract comprises sugars, the extract mainly comprises monosaccharides and oligosaccharides with molar masses of between 360 Da and 1,260 Da. Advantageously, the extract according to the invention comprises at least one sugar chosen from glucose, galacturonic acid, fructose, galactose, xylose, mannose, arabinose, and combinations thereof.

[0037] To improve the production yield of the active ingredient, at least one hydrolysis is carried out. Thus, according to a particularly interesting object, the extract of Nasturtium officinale is obtained from a hydrolysis, more preferably an enzymatic hydrolysis. Advantageously, the extract of Nasturtium officinale is a hydrolyzate of Nasturtium officinale.

[0038] More preferably, the hydrolyzate of Nasturtium officinale is an enzymatic hydrolyzate of Nasturtium officinale.

[0039] According to a particularly preferred object of the invention, the extract is capable of being obtained by a preparation process comprising the following steps: a. Solubilization of Nasturtium officinale, in water at a rate of at least 50 g / L, preferably aerial parts of Nasturtium officinale b. Extraction by hydrolysis, preferably enzymatic hydrolysis c. Separation of the soluble and insoluble phases, preferably by decantation, filtration or centrifugation, d. Heat treatment, e. Concentration of the soluble phase, preferably by filtration, atomization, or lyophilization. f. Possibly, deodorization and / or discoloration, g. Optionally, filtration and sterilizing filtration

[0040] The cosmetic active ingredient according to the invention advantageously comprises at least one excipient chosen from a preservative, an antioxidant, a stabilizer, an atomization support and / or their combination.

[0041] The extract according to the invention present in the cosmetic active ingredient can be in liquid form or in solid form or in film form.

[0042] When it is presented in liquid form, the active ingredient according to the invention consists exclusively of the extract of Nasturtium officinale accompanied by a stabilizer and / or preservation system.

[0043] The extract in liquid form is preferably in the form of a clear liquid aqueous solution, with a weak odor and a light yellow to yellow color. It may, however, be less colored.

[0044] The dry matter content of the extract can be determined by weighing the residues resulting from drying the extract according to the invention at 105°C in an oven until a constant weight is obtained. Preferably, the extract according to the invention in liquid form has a dry matter content of 20 g / L to 100 g / L, preferably of 40 g / L to 60 g / L.

[0045] When it is in solid form, the active ingredient according to the invention is preferably constituted by the extract of Nasturtium officinale as previously described and by a support chosen from maltodextrin, gum arabic or soy lecithin. According to a particularly suitable embodiment, the extract represents at least 10% by weight of the active ingredient and the support at most 90% by weight of the active ingredient.

[0046] In the case of a solid form in which the active ingredient is associated with a support, the mineral, protein and sugar contents in the active ingredient are modified, the support generally consisting mainly of sugars.

[0047] The active ingredient according to the invention can also be presented in the form of a film such as as described in patent FR3079145. In this case, the Nasturtium officinale extract represents at least 0.1% by weight of the film.

[0048] When it is in the form of a film, the active ingredient comprises: - at least the extract of Nasturtium officinale according to the invention. - at least one mineral filler, and - at least one polymer of natural origin, and - at least one plasticizer, and - at least one surfactant.

[0049] The polymer of natural origin can be chosen from: Pectin, Tamarind gum, Alginate, Pullulan, Psyllium, Xanthan, Guar, Tara, Carob, Agar, Gum arabic, Gellan, Dextran, Carrageenan, Cellulose, Konjac and Chitosan.

[0050] The plasticizer can be chosen from: Glycerol, Sorbitol, Sucrose, Erythritol, Urea, Propylene glycol and Butylene glycol.

[0051] The mineral filler can be chosen from: Calcium carbonate, green clay, kaolin, perlite, talc, magnesium silicate, mica, diatomaceous sericite, silica, calcium sulfate, calcium chloride, potassium chloride, iron oxide and zinc oxide.

[0052] The active ingredient may further comprise a pigment for coloring the film.

[0053] Composition according to the invention

[0054] The active ingredient according to the invention may optionally be integrated into a composition, in particular a composition comprising at least 0.1% by weight of said active ingredient and a physiologically acceptable medium, preferably a cosmetically acceptable medium.

[0055] These compositions may be in particular in the form of oil-in-water emulsions, water-in-oil emulsions, multiple emulsions (Water / Oil / Water or Oil / Water / Oil) which may optionally be microemulsions or nanoemulsions, or in the form of solutions, suspensions, hydrodispersions, aqueous gels, powders, or foundation or in the form of a film. They may be more or less fluid and have the appearance of creams, emulsions, gels, masks or any other aspects known to those skilled in the art.

[0056] Preferably, these may be compositions comprising between 0.1 and 20% of the liquid active ingredient according to the invention, more preferably between 0.5 and 10%.

[0057] These compositions comprise, in addition to the active ingredient, a physiologically acceptable medium such as a cosmetically acceptable medium, that is to say which does not cause sensations of discomfort for the user such as redness, tightness or tingling.

[0058] The compositions according to the invention may also contain as an ingredient at least one compound chosen from: - oils, which can be chosen in particular from silicone oils, linear or cyclic, volatile or non-volatile, - waxes, such as ozokerite, polyethylene wax, beeswax or camauba wax, - silicone elastomers, - surfactants, preferably emulsifying surfactants, whether non-ionic, anionic, cationic or amphoteric, - co-surfactants, such as linear fatty alcohols, - thickeners and / or gelling agents, - humectants, such as polyols like glycerin, - colorants, preservatives, fillers, - tensors, - sequestrants, - perfumes, - and their mixtures, without this list being exhaustive.

[0059] Examples of such ingredients are cited in particular in the CTFA Dictionary (International Cosmetic Ingredient Dictionary and Handbook published by the Personal Care Product Council).

[0060] Of course, those skilled in the art will take care to choose the possible complementary compounds, active or non-active, and their quantity, in such a way that the advantageous properties of the mixture are not, or not significantly, altered by the envisaged addition.

[0061] Process for preparing the extract according to the invention

[0062] The extract constituting or contained in the active ingredient according to the invention can be obtained by any means.

[0063] Watercress is a fast-growing plant that requires little fertilizer. It is best grown in watercress beds by successive sowings.

[0064] According to a preferred embodiment, the extraction process comprises at least one step of solubilization of Nasturtium officinale, preferably of the aerial parts of Nasturtium officinale, a hydrolysis step, preferably at least one enzymatic hydrolysis and a filtration step.

[0065] According to a particularly suitable embodiment, the active ingredient according to the invention is obtained by implementing the following steps: a. Solubilization of aerial parts of Nasturtium officinale, in water at a rate of at least 50 g / L, b. Hydrolysis, preferably enzymatic hydrolysis, c. Separation of soluble and insoluble phases, d. Heat treatment, e. Concentration of the soluble phase, preferably by molecular sorting, f. Optionally, deodorization and / or discoloration, g. Optionally, filtration and sterilizing filtration.

[0066] The heat treatment step is advantageously carried out to inactivate the enzyme(s) present. This inactivation is then carried out according to the recommendations of the supplier of the enzyme(s) used.

[0067] The separation of the soluble and insoluble phases is carried out by any means known to those skilled in the art, for example by centrifugation, filtration or decantation. The separation of the soluble and insoluble phases is carried out to recover the soluble phase.

[0068] The molecular sorting step allows the concentration / purification of the recovered soluble phase. It is carried out in order to more specifically select the active molecules.

[0069] The extract obtained after hydrolysis and concentration, before or after concentration and sterilizing filtration, is an extract of Nasturtium officinale, and constitutes a first form of the active ingredient according to the invention, then appearing in liquid form.

[0070] The extract obtained can then be dried and associated or not with a support, to be presented in solid form. This phase can be carried out by implementing the following steps: - an atomization support, preferably maltodextrin, is added to the Nasturtium officinale extract, at most 90% (mass / volume); - this solution is then concentrated under vacuum; - antimicrobial treatment can be carried out; - atomization makes it possible to obtain a powder.

[0071] The extract obtained can also be used to be presented in the form of a film. This phase can be carried out by implementing the following steps: - Formulation in liquid form of the different components: extract of Nasturtium officinale according to the invention, mineral filler, polymer of natural origin, plasticizer, surfactant, - Filing the formula on a support, - Evaporation of water in an oven heated to a temperature between 70 and 100°C, - Laser cutting according to the desired shape.

[0072] The steps of the processes described above, taken individually, are customary in the field of extractions of active ingredients from natural raw materials and those skilled in the art are able to adjust the reaction parameters on the basis of their general knowledge.

[0073] Use of the active ingredient according to the invention

[0074] Finally, as mentioned previously, the inventor was particularly interested in this plant species to develop an active ingredient to act on stress and its harmful effects.

[0075] Thus, the invention relates to an extract of Nasturtium officinale, in particular an active ingredient comprising said extract of Nasturtium officinale, according to any of the objects previously described, for its cutaneous use to combat stress.

[0076] Indeed, surprisingly, the inventor observed that the active ingredient according to the invention makes it possible to combat stress and its consequences on skin cells. Thus, the invention relates preferentially to the active ingredient of the invention for combating the cutaneous effects linked to stress, by stimulating the mediators of well-being, in particular by acting on the oxytocin pathway and the endocannabinoid pathway but also by exhibiting a myorelaxant action via the neuromuscular junction.

[0077] Indeed, during his research work, the inventor observed that the active ingredient according to the invention has an efficacy on the actors of paracrine communication between keratinocytes and nerve endings. The oxytocin system and the cellular signaling linked to the CB1R receptor were studied in order to demonstrate that the active ingredient according to the invention stimulates the mediators and receptors of well-being via the stimulation of the secretion of oxytocin (OXT), as well as the induction of the expression of the PIEZO1 and OXTR and CB1R receptors.

[0078] Oxytocin is a neuropeptide synthesized in the hypothalamus in response to a feeling of well-being but also in response to touch. This so-called happiness hormone plays an important role in social interactions by regulating, in particular, feelings of anxiety, friendship, attachment to others and empathy. At the cutaneous level, oxytocin (OXT) is secreted in the epidermis and dermis. Its receptor (OXTR), also expressed in the skin, belongs to the family of G protein-coupled receptors. Following the binding of oxytocin, it allows the activation of intracellular signaling pathways. This receptor is involved in the mediation of well-being and its activation depends in particular on minerals.

[0079] The PIEZO1 mechanoreceptor is an ion channel expressed by keratinocytes and nerve endings. It stimulates sensory nerve fibers and transmits the sensation of touch to the skin. Recently, it has been shown that activation of PIEZO1 by gentle tactile stimulation can induce oxytocin secretion by keratinocytes.

[0080] The endocannabinoid pathway is also well known for its beneficial effect both at the mental level and at the level of peripheral tissues such as the skin. The cannabinoid receptor type 1 (CB1R) is a G protein-coupled membrane receptor whose cellular signaling is dependent on minerals. Expressed at the cutaneous level, this receptor participates in maintaining epidermal homeostasis and strengthens the barrier function.

[0081] Thus, the active ingredient according to the invention has an action on the oxytocin and cutaneous endocannabinoid pathways, via the stimulation of oxytocin (OXT), PIEZO1, OXTR receptors, but also the CB1R receptor, pathways well known to be involved in well-being and the fight against stress. In a particularly surprising manner, the effect is immediate with an improvement in neurostimulation, from 6 hours after application.

[0082] Thus, the invention advantageously has as its subject, the active principle for its use: - to increase cutaneous oxytocin (OXT) secretion, and / or - to increase the expression of the PIEZO1 receptor and / or - to increase the expression of the OXTR receptor, and / or - to increase the synthesis of the cannabinoid receptor type 1 (CB1R).

[0083] Thus, the active ingredient stimulates the production of the happiness hormone: oxytocin, reducing stress levels and improving skin quality. The complexion's radiance is then enhanced.

[0084] According to another object, the active ingredient according to the invention also has a myorelaxant action and reduces muscle contraction. Indeed, at the molecular level, the contraction of facial muscles results from the stimulation of motor neurons and the release of the messenger of muscle contraction, acetylcholine, at the neuromuscular synapses. In response to a nerve impulse, mineral exchanges take place and lead to the fusion of acetylcholine vesicles contained in the nerve ending at the pre-synaptic membrane. Once released into the synaptic cleft, acetylcholine binds to specific receptors located on the surface of the muscle fiber. Mineral exchanges occur and induce the triggering of a muscle contraction.

[0085] The active ingredient according to the invention has a myorelaxant effect. This effectiveness on the neuromuscular junction results in a smoothing effect, preferably an immediate smoothing effect. Indeed, the inventor observed a smoothing effect as early as 5 days after application. Thus, the invention also relates to the active ingredient according to the invention for its use, said active ingredient has a cutaneous myorelaxant effect and / or a smoothing effect. Preferably the smoothing effect is immediate. This effectiveness also results in a “soft focus” effect of the active ingredient according to the invention. The effect perceived by the volunteers is similar to that obtained with a photo retouching filter.

[0086] The invention is now illustrated by non-limiting examples of compositions according to the invention and by results. Examples

[0087] Example 1: Active ingredient according to the invention

[0088] The active ingredient of Example 1 is obtained from the plant species Nasturtium officinale. The active ingredient of Example 1 is obtained by the following process: a. Solubilization of aerial parts of Nasturtium officinale, in water at a rate of at least 50 g / L, b. Enzymatic hydrolysis, c. Separation of soluble and insoluble phases, d. Heat treatment, and e. Concentration of the soluble phase.

[0089] The active ingredient according to example 1 consists of an extract of Nasturtium officinale comprising at least 25% minerals.

[0090] The active ingredient obtained has in particular the following characteristics: - Dry Matter Content = 52.8 g / L, including: - Mineral ash content = 23 g / L or 44% by weight compared to the dry matter - Total Sugar Content = 13.8 g / L or 26%, by weight relative to dry matter - Protein content = 9%, by weight relative to dry matter

[0091] Example 2: Composition according to the invention

[0092] An example of a formulation comprising the active ingredient according to the invention in the form of a gel-cream is presented in Table 1 below.

[0093] [Tables 1] Ingredients % A Purified Water qs 100 Glycereth-26 3.00 B Sodium Acrylate / Sodium Acryloyldimethyl Taurate Copolymer & C15-19 Alkane & Polyglyceryl-6 Laurate & Polyglycerin-6 1.50 Coco-Caprylate 4.50 Triheptanoin 3.50 Cetearyl Ethylhexanoate 2.50 Acrylates / C 10-30 Alkyl Acrylate Crosspolymer 0.30 C Soda Solution 28% qsp pH D Butylene Glycol 5.00 Boron Nitride 0.75 E Active Principle Invention 2.00

[0094] The composition according to example 2 can in particular be obtained by the following process: - Add B to A while stirring vigorously. Stir for 20 minutes. - Adjust the pH with C to 6.0 - 6.5. - With moderate stirring, add premix D then E.

[0095] The composition is then in the form of a thick, white and shiny cream-gel, having a pH of 6.3 and a viscosity (C / 5rpm) equal to 35,000cP.

[0096] Example 3: Composition according to the invention

[0097] An example of a formulation comprising the active ingredient according to the invention in the form of a well-being mask with a fresh cream gel texture is presented in Table 2 below.

[0098] [Tables2] Ingredients % Al Purified Water qsp 100 Preservative qs Butylene Glycol 3.00 A2 Glycerin 2.00 Sclerotium Gum & Xanthan Gum 0.20 B Sodium Stearoyl Glutamate 0.25 Pentaerythrityl Distearate 1.50 Isocetyl Stearoyl Stearate 3.00 Cetearyl Ethylhexanoate 5.00 Diisopropyl Adipate 4.00 Dimethicone 3.00 C Hydroxyethyl Acrylate / Sodium Acryloyl-dimethyl Taurate Copolymer & Poly-isobutene & PEG-7 Trimethylolpropane Coconut Ether 2.00 D Active Ingredient Invention 2.00 E Citric Acid Solution 10% qsp pH

[0099] The composition of Example 3 can in particular be obtained by the following process: - Add A2 to Al while stirring and heat to 80°C. - Place B under stirring and heat to 80°C. - Emulsify B in A under shearing agitation for 10 minutes. - At room temperature, with gentle stirring, add C then D. - Adjust pH to 5.0 - 5.5 with E.

[0100] The composition is then in the form of a mask having the texture of a thick, white gel-cream, with a pH of 5.3 and a viscosity (C / 5rpm) equal to 58,000cP.

[0101] Example 4: Composition according to the invention

[0102] An example of a formulation comprising the active ingredient according to the invention in the form of a relaxing anti-wrinkle face cream is presented in Table 3 below.

[0103] [Tables3] Ingredients % Al Purified Water qsp 100 Preservative qs Butylene Glycol 3.00 A2 Glycerin 2.00 Xanthan Gum 0.20 B Cetyl Alcohol & Glyceryl Stearate & PEG-75 Stearate & Ceteth-20 & Steareth-20 4.00 Squalane 4.00 Undecane & Tridecane 5.00 Jojoba Esters & Jojoba Alcohol & Pro-panediol & Tocopherol 4.00 Isocetyl Stearoyl Stearate 5.00 Dimethicone 3.00 C Polymethylsilsesquioxane 4.00 D Hydroxyethyl Acrylate / Sodium Acryloyl-dimethyl Taurate Copolymer 0.50 E Parfum (Fragrance) 0.50 F Active Ingredient Invention 2.00 G Soda Solution 28% qsp pH

[0104] The composition of Example 4 can in particular be obtained by the following process: - Add A2 to Al with moderate stirring, and heat to 80°C. - Place B under stirring and heat to 80°C. - Emulsify B in A under shearing agitation for 10 minutes. - At 40°C, with gentle stirring, add C, D, E and F. - Adjust the pH to 5.2 - 5.6 with G.

[0105] The composition is then in the form of a flexible, shiny, off-white emulsion, with a pH of 5.4 and a viscosity (C / 5rpm) of 24,000cP, spreading easily on the skin and leaving a soft and comfortable finish.

[0106] Example 5: Composition according to the invention

[0107] An example of a formulation comprising the active ingredient according to the invention in the form of a smoothing primer is presented in Table 4 below.

[0108] [Tables4] Ingredients % Al Purified Water qs 100 Preservative qs Butylene Glycol 3.00 A2 Glycerin 2.00 Sclerotium Gum & 100 cSt 6.00 Dimethicone & Dimethicone Crosspolymer 10.00 C Polyacrylate Crosspolymer-6 0.50 D Mica 1.50 Kaolin 1.50 E CI 77891 (Titanium Dioxide) & Mica & CI 77491 (Iron Oxides) 0.20 F Active Ingredient Invention 2.00

[0109] The composition of Example 5 can in particular be obtained by the following process: - Add A2 to Al with moderate stirring, and heat to 80°C. - Place B under stirring until homogeneous and heat to 80°C. - Emulsify B in A under shearing agitation for 10 min. - At 40°C, add C then D, E and F with moderate stirring.

[0110] The composition is then in the form of a soft, peach-colored emulsion, preparing the skin for the application of flawless makeup. Its soft texture is pleasant to apply and smooths imperfections for a natural finish. [YES] Evaluation of the effectiveness of the active ingredient according to the invention

[0112] Test 1 - Study of the active fraction of the active ingredient according to the invention

[0113] The objective of this study is to identify the active fraction of the active ingredient of the invention. This is rich in mineral ash (at least 25% of the active ingredient), to carry out this study, the effectiveness of the active ingredient according to the invention is compared to that of the extract constituting the active ingredient of the invention demineralized, by electrodialysis. We then obtain a product devoid of 96% of the mineral salts present in the initial extract, hereinafter called “demineralized extract”.

[0114] The objective of this study is to compare the capacity of the active ingredient according to the invention and the demineralized extract to modulate the expression of the OXTR (Oxytocin receptor) gene involved in the well-being pathways. This study is carried out by quantitative PCR on normal human keratinocytes. The results are presented in Table 5, below.

[0115] [T ableaux5 ] Expression of OXTR (%) Ability to boost the expression of OXTR (%) Control 100 INVENTION 0.50% 666 + 19 +566 Demineralized extract 0.50% 98 + 8 +0

[0116] The active ingredient according to the invention increases the expression of the OXTR gene by +566% while the demineralized extract does not modify the expression of said gene. Thus, it is the minerals present in the extract which are responsible for the stimulation of the expression of OXTR.

[0117] Test 2 - Study of the active ingredient according to the invention on muscle contraction

[0118] The objective of this study is to evaluate the capacity of the active ingredient according to the invention to reduce the frequency of contractions of muscle cells and consequently to evaluate the myorelaxant effect.

[0119] This study was carried out on a model of human sensory neurons derived from hiPS cells (human induced pluripotent stem cells) in co-culture with human muscle cells. The number of muscle contractions was monitored and recorded using a microscope equipped with a camera.

[0120] The protocol is as follows. Motor neurons from hiPS cells are cultured with human muscle cells. The culture medium was changed regularly.

[0121] The active ingredient according to the invention at 0.5%, 1.0% or 2.0% is added to the culture wells. A positive control exhibiting myorelaxant activity was used at 2 pM. The number of contractions is counted after 6 hours.

[0122] The number of contractions is determined for 1 minute and the results are expressed as a percentage according to the following formula.

[0123] [Math.l] Number of contractions to - Number of contractions to to Percentage of contractions =---------------------------------------------------x1D0 Number of contractions ta

[0124] The results are presented in Table 6, below.

[0125] [Tableauxô] Percentage of contractions (%) Ability to reduce the percentage of contractions (%) Control 8 Positive control 2pM -21 -29 INVENTION 0.5% -21 -29 INVENTION 1.0% -25 -33 INVENTION 2.0% -31 -39

[0126] From a dose of 0.5%, the active ingredient according to the invention significantly inhibits muscle contractions in a nerve-muscle co-culture model, with a dose effect observed up to 2%. Thus, the active ingredient according to the invention exhibits myorelaxant activity.

[0127] Test 3 - Study of the active ingredient according to the invention on the mediators of well-being

[0128] Test 3a - Study on the oxytocin and endocannabinoid pathways.

[0129] The objective of this study is to evaluate the capacity of the active ingredient according to the invention to stimulate the mediators and receptors of well-being, in particular involved in the oxytocin and endocannabinoid pathways.

[0130] The study was carried out through the analysis of: - the expression of PIEZO1, OXT and OXTR by quantitative PCR on human keratinocytes from donors of median age (54 years); - the synthesis of oxytocin and the cannabinoid receptor type 1 (CB1R), by ELISA assay and immunohistofluorescence labeling, on human skin explants from donors with a median age of 38 years.

[0131] The protocol for studying the expression of PIEZO1, OXT and OXTR is as follows. Human keratinocytes are seeded and incubated, then the cells are treated with culture medium containing the active ingredient according to the invention at 0.25% or 0.50% (V / V). Finally, the keratinocytes are recovered and the total RNA extracted, then analyzed by the quantitative PCR technique.

[0132] The protocol for the study of oxytocin synthesis and the cannabinoid receptor type 1 (CB1R) is as follows. Human skin explants were made and kept alive in a suitable culture medium, then the explants are treated every days in systemic mode with the active ingredient according to the invention at 0.5% and 1.0% (WV) for several days. The sub-natants are collected and measured by an ELISA test in order to measure the synthesis of oxytocin.

[0133] Regarding the study on the type 1 cannabinoid receptor (CB1R), the explants are recovered, fixed, dehydrated and embedded in paraffin. Sections are then made, then labeled with an anti-CBIR primary antibody and a secondary antibody, and finally, visualized by microscope.

[0134] The results of the expression of PIEZO1, OXT and OXTR are presented in Table 7 below.

[0135] [Tables?] Expression (%) Ability to increase expression (%) PIEZO1 Control 100 INVENTION 0.25% 135 +35 INVENTION 0.50% 187 +87 OXT Control 100 INVENTION 0.25% 141 +41 INVENTION 0.50% 275 +175 OXTR Control 100 INVENTION 0.25% 239 +139 INVENTION 0.50% 651 +551

[0136] Tested at 0.5% on human keratinocytes, the active ingredient according to the invention significantly increases the expression of PIEZO1, oxytocin and its receptor by 87%, 175% and 551% respectively.

[0137] The results of the synthesis of oxytocin are presented in Table 8, below.

[0138] [Tables8] Oxytocin synthesis (pg / mL) Ability to increase oxytocin synthesis (%) Control 30 INVENTION 0.5% 41 +37 INVENTION 1.0% 49 +63

[0139] Tested at 1.0% on human skin explants, the active ingredient according to the invention significantly increases oxytocin synthesis by 63%.

[0140] The results of the synthesis of CB1R are presented in Table 9, below.

[0141] [Tables9] CB1R synthesis (UA) Ability to increase CB1R synthesis (%) Control 24 INVENTION 0.5% 33 +38 INVENTION 1.0% 35 +46

[0142] Tested at 1.0% on human skin explants, the active ingredient according to the invention significantly increases the synthesis of the type 1 cannabinoid receptor by 46%.

[0143] Tested on human keratinocytes and explants, the active ingredient according to the invention acts on the oxytocin and endocannabinoid pathways. It thus stimulates the mediators and receptors of well-being.

[0144] Test 3b - Study of epidermal proliferation and differentiation

[0145] At the skin level, the effects of psychological stress result in a disruption of the proliferation process and an alteration of the barrier function. It has recently been demonstrated that activation of the endocannabinoid pathway, more particularly the type 1 receptor (CB1R), as well as the oxytocin pathway stimulate epidermal proliferation. In addition, CB1R signaling is necessary for optimal differentiation of the epidermis and the maintenance of an intact barrier function. In this context, the inventor evaluated the ability of the active ingredient according to the invention to stimulate keratinocyte proliferation and epidermal differentiation.

[0146] The objective of this study is to evaluate the capacity of the active ingredient according to the invention to stimulate keratinocyte proliferation and differentiation.

[0147] The role of protecting the epidermis against the external environment is ensured by keratinocytes which will on the one hand proliferate and contribute to tissue renewal, and on the other hand differentiate and enter into different stages of maturation to generate an effective barrier function.

[0148] Filaggrin is an essential element in the epidermal barrier function because it contributes to the rigidity of the tissue as well as its hydration.

[0149] The protocol is identical to that described in the study of the synthesis of the type 1 cannabinoid receptor (Trial 3a), except that the primary antibody is an anti-filaggrin antibody.

[0150] The results of cell proliferation are shown in Table 10, below.

[0151] [TableauxlO] Proliferation (AU) Capacity to increase proliferation (%) Control 81,380 INVENTION 0.25% 130,823 +61 INVENTION 0.50% 137,363 +69

[0152] Tested at 0.5% on human keratinocytes, the active ingredient according to the invention significantly increases their proliferation by 69%.

[0153] The results of the synthesis of filaggrin are presented in Table 11, below.

[0154] [T ables 11] Filaggrin synthesis (UA) Ability to increase filaggrin synthesis (%) Control 789 INVENTION 0.5% 974 +23 INVENTION 1.0% 990 +25

[0155] Tested at 1.0% on human skin explants, the active ingredient according to the invention significantly increases the synthesis of filaggrin by 25%.

[0156] Tested on human keratinocytes and explants, the active ingredient according to the invention promotes proliferation and differentiation, thus making it possible to regulate epidermal homeostasis.

[0157] Test 4 - In vivo study of the smoothing effect of the active ingredient according to the invention

[0158] The objective of this study is to evaluate in vivo the smoothing effect of the active ingredient according to the invention formulated at 2% in emulsion after 5 and 28 days of twice-daily application to the entire face, compared to a placebo formula.

[0159] The study was conducted on a Caucasian panel, including a young group with first expression lines. The young group consisted of 16 healthy female volunteers (average age 35 years) compared to the placebo group of 16 healthy female volunteers (average age 35 years). All subjects were selected according to a moderate to high stress level according to the Perceived Stress Scale (PSS10) questionnaire.

[0160] The smoothing effect is evaluated using a fringe projection device dedicated to the 3D measurement of skin relief. The parameter retained for this study is the roughness parameter Rz which reflects the depth of the wrinkles. The higher this parameter, the greater the depth of the furrows.

[0161] The results are presented in Table 12, below.

[0162] [Tables 12] Variation / D0 (%) Forehead Crow's feet Glabella Nasolabial fold Placebo -0.4 -1.2 -0.2 -0.1 INVENTION -3.6 0.9 -5.3 -3.9 Variation / Placebo (%) -3.2 2.1 -5.1 -3.8

[0163] The active ingredient according to the invention promotes the rapid smoothing (in only 5 days of twice-daily application to the entire face) of the first expression lines in young Caucasian volunteers compared to the placebo, in particular at the level of the forehead, the glabella and the nasolabial fold.

[0164] Thus, the first expression lines of young volunteers are smoothed out quickly.

[0165] Test 5 - In vivo study on the “soft focus” effect on the face

[0166] The study protocol is identical to that of trial 4. Standardized photographs of the face, without expression, were taken from the front and the side.

[0167] The photographs were retouched by image analysis experts using computer software to smooth the face by targeting the appearance of wrinkles. The evaluation was carried out by a panel of naive evaluators in comparison with real images. The evaluators judged the overall improvement in the appearance of the volunteer's face by comparing the reference image, taken before the start of treatment, and the images to be evaluated: the image retouched using software, the photograph at D5 after application, the photograph at D28 after application.

[0168] The results are presented in Table 13, below.

[0169] [Tables 13] Average Improvement (AU) Placebo INVENTION 2% Retouched Image 1.41 1.40 J5 0.81 1.08 J28 0.72 1.14

[0170] From 5 days of twice-daily application, the active ingredient according to the invention at 2% allows young Caucasian volunteers to obtain a visible result approaching that obtained with photo retouching. This effect intensifies after 28 days of treatment, at which point the score given to the retouched image is no longer significantly different from that given to the image after application.

[0171] Test 6 - In vivo study on the well-being of the active ingredient according to the invention

[0172] The study protocol is identical to that of trial 4, including the young panel Caucasian. Among the 16 volunteers included in this group, oxytocin labeling was performed on 12 subjects (mean age 36 years). The study protocol was also carried out on a mature panel with established expression lines. This panel is composed of 17 subjects (mean age 57 years). Among these volunteers, labeling was performed on 12 subjects (mean age 58 years). The amount of oxytocin produced in the forearms was measured by immunocytofluorescence. Oxytocin synthesis is proportional to fluorescence intensity. The greater the fluorescence, the higher the oxytocin synthesis.

[0173] The results are presented in Table 14 (young panel) and 15 (mature panel), below.

[0174] [Tablesl4] Variation / D0 (%) Variation / Placebo (%) Placebo INVENTION D5 5.1 70.3 65 D28 -10.6 63.6 74

[0175] [Tablesl5] Variation / D0 (%) Variation / Placebo (%) Placebo INVENTION D5 16.3 153.3 137 D28 23.4 162.4 139

[0176] From 5 days of twice-daily application and in comparison with the placebo, the active ingredient according to the invention at 2% increases the production of oxytocin in young volunteers by 65% ​​and in mature volunteers by 137%. These effects are further intensified after 28 days of treatment with an increase in oxytocin production of 74% in young volunteers and 139% in mature volunteers.

[0177] The effect of the active ingredient according to the invention on the perception of stress was also determined using an evaluation questionnaire. For this study, the Perceived Stress Scale (PSS10) was used. It is based on the transactional approach to stress in order to understand the psycho-cognitive mechanisms of the latter.

[0178] The results corresponding to the perception of stress of the subjects who participated in the evaluation of the placebo formula or the formula comprising the active ingredient according to the invention formulated at 2% for 28 days, are presented in tables 16 (young panel) and 17 (mature panel), below.

[0179] [Tableauxlô] Variation / D0 Variation / Placebo (%) Placebo -10.4 INVENTION -15.2 -4.9

[0180] [Tablesl7] Variation / D0 Variation / Placebo (%) Placebo -7.6 INVENTION -16.6 -9.0

[0181] After 28 days of twice-daily use of the active ingredient according to the invention at 2%, all young or mature subjects noted a reduction in perceived stress in their daily lives. This effect was observed: - in 75% of young subjects having used the active ingredient according to the invention against 56% of subjects having applied the placebo formula; - in 71% of mature subjects who used the active ingredient according to the invention compared to 59% of subjects who applied the placebo formula.

[0182] In conclusion, after 5 days of twice-daily application by young and mature volunteers, the active ingredient according to the invention formulated at 2% in emulsion stimulates the production of the happiness hormone oxytocin. These effects are prolonged and intensified after 28 days of treatment.

[0183] Furthermore, compared to treatment with a placebo emulsion, the active ingredient according to the invention allows young and mature volunteers to feel better about themselves and thus to perceive less daily stress.

[0184] Test 7 - In vivo study on skin tone radiance

[0185] The study protocol is identical to that of trial 5, including the Caucasian panel.

[0186] The effect of the active ingredient according to the invention was evaluated on the face after 5 and 28 days of twice-daily application analyzing complexion radiance on digital photographs.

[0187] The results are presented in Table 18 below.

[0188] [Tablesl8] Variation / Placebo (%) Radiation Pink color Olive color Eye fatigue D5 5.6 28.8 -11.0 -15.3 D28 11.5 34.7 -12.7 -16.3

[0189] In just 5 days of application, the active ingredient according to the invention formulated at 2% significantly improves the characteristic parameters of the radiance of the complexion of young Caucasian volunteers. Indeed, the active ingredient according to the invention makes the complexion brighter, fresher and improves the healthy glow by reducing olive color and eye fatigue (significant effects compared to the placebo).

[0190] These effects further improved after 28 days of treatment with an 11.5% increase in skin radiance and a 34.7% increase in pink color. There was also a 12.7% decrease in olive color and a 16.3% decrease in eye fatigue in 50% of volunteers.

[0191] From 5 days of twice-daily application by young Caucasian volunteers, the active ingredient according to the invention at 2% improves the radiance of the skin complexion.

[0192] This effect is maintained after 28 days of application.

[0193] In conclusion, the active ingredient according to the invention makes it possible to combat stress, in particular its harmful effects, by acting on the oxytocin and endocannabinoid pathway, in particular the receptors and mediators of well-being, which results in an improvement in the radiance of the skin complexion, and therefore makes it possible to combat skin stress.

Claims

Claims

1. Active ingredient comprising at least one extract of Nasturtium officinale, for its cutaneous use to combat stress, characterized in that the extract of Nasturtium officinale comprises minerals.

2. Active ingredient for its use according to the preceding claim, to combat the cutaneous effects of stress.

3. Active ingredient for its use according to one of the preceding claims, characterized in that said active ingredient has a cutaneous myorelaxant effect.

4. Active ingredient for its use according to one of the preceding claims, characterized in that said active ingredient stimulates the mediators and receptors of well-being.

5. Active ingredient for its use according to the preceding claim, characterized in that said active ingredient increases the secretion of cutaneous oxytocin (OXT).

6. Active ingredient for its use according to one of the preceding claims, characterized in that said active ingredient increases the expression of the PIEZO1 receptor.

7. Active ingredient for its use according to one of the preceding claims, characterized in that said active ingredient increases the expression of the OXTR receptor.

8. Active ingredient for its use according to one of the preceding claims, characterized in that said active ingredient increases the synthesis of the type 1 cannabinoid receptor (CB1R).

9. Active ingredient for its use according to one of the preceding claims, characterized in that the extract of Nasturtium officinale is a hydrolyzate of Nasturtium officinale.

10. Active ingredient for its use according to the preceding claim, characterized in that the hydrolyzate of Nasturtium officinale is an enzymatic hydrolyzate of Nasturtium officinale.

11. Active ingredient for its use according to one of the preceding claims, characterized in that the minerals represent at least 25% by weight of the total weight of the extract

12. Active ingredient for its use according to one of the preceding claims, characterized in that the extract comprises at least one mineral chosen from chlorides, sulfur, sodium, potassium, magnesium, phosphorus, calcium, and combinations thereof.

13. Cosmetic use of an active ingredient according to one of the preceding claims, to improve the radiance of the complexion.

14. Cosmetic use of an active ingredient according to one of claims 1 to 12, for an immediate smoothing effect.

Citation Information

Patent Citations

  • USE OF A DRY FILM FOR TOPICAL COSMETIC APPLICATIONS

    FR3079145A1

  • Production of a plant-derived active ingredient useful in cosmetic moisturizing products comprises enzymatic hydrolysis of an aqueous dispersion of watercress powder

    FR2834462B1